Umeclidinium bromide/vilanterol
 | |
 Umeclidinium bromide (top), vilanterol (bottom) | |
| Combination of | |
|---|---|
| Umeclidinium bromide | Anticholinergic |
| Vilanterol | Beta2-adrenergic agonist |
| Clinical data | |
| Trade names | Anoro Ellipta |
| AHFS/Drugs.com | anoro-ellipta |
| Routes of administration | Inhalation |
| ATC code | |
| Legal status | |
| Legal status |
|
Umeclidinium bromide/vilanterol (trade name Anoro Ellipta) is a combination drug approved for the treatment of chronic obstructive pulmonary disease (COPD).[1][2] It is applied as an inhalation.
References
- ^ Feldman, GJ; Edin, A (2013). "The combination of umeclidinium bromide and vilanterol in the management of chronic obstructive pulmonary disease: Current evidence and future prospects". Therapeutic advances in respiratory disease. 7 (6): 311–9. doi:10.1177/1753465813499789. PMID 24004659.
- ^ "FDA Approves Umeclidinium and Vilanterol Combo for COPD". Medscape. December 18, 2013.
 | This drug article relating to the respiratory system is a stub. You can help Wikipedia by expanding it. |